The Developmental Journey of Therapies Targeting Purine Receptors: from Basic Science to Clinical Trials

Overview

Journal Purinergic Signal

Publisher Springer

Date 2022 Sep 29

PMID 36173587

Authors

Seunga Han

Haruna Suzuki-Kerr

Srdjan M Vlajkovic

Peter R Thorne

Affiliations

Soon will be listed here.

Abstract

Since the discovery of ATP as an extracellular signalling molecule in 1972, purinergic signalling, mediated by extracellular purines and pyrimidines has been identified in virtually all mammalian tissues and is implicated in regulating fundamental cellular processes. In recent years, there has been an increasing focus on the pathophysiology and potential therapeutic interventions based on purinergic signalling. A vast range of compounds targeting purine receptors are in clinical development, and many more are in preclinical studies, which highlights the fast growth in this research field. As a tribute to Professor Geoffrey Burnstock's legacy in purinergic signalling, we present here a brief review of compounds targeting purine receptors that are in different stages of clinical trials. The review highlights the 50-year journey from basic research on purinergic receptors to clinical applications of therapies targeting purine receptors.

Citing Articles

Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.

Al-Aqtash R, Collier D Channels (Austin). 2024; 18(1):2355150.

PMID: 38762911 PMC: 11110710. DOI: 10.1080/19336950.2024.2355150.

Increased Purinergic Signaling in Human Dental Pulps With Inflammatory Pain is Sex-Dependent.

See L, Sripinun P, Lu W, Li J, Alboloushi N, Alvarez-Periel E J Pain. 2023; 25(4):1039-1058.

PMID: 37956743 PMC: 11129867. DOI: 10.1016/j.jpain.2023.10.026.

Alterations of Purinergic Receptors Levels and Their Involvement in the Glial Cell Morphology in a Pre-Clinical Model of Autism Spectrum Disorders.

Babiec L, Wilkaniec A, Matuszewska M, Palasz E, Cieslik M, Adamczyk A Brain Sci. 2023; 13(7).

PMID: 37509018 PMC: 10377192. DOI: 10.3390/brainsci13071088.

Research Progress in the Relationship Between P2X7R and Cervical Cancer.

Tang Y, Qiao C, Li Q, Zhu X, Zhao R, Peng X Reprod Sci. 2022; 30(3):823-834.

PMID: 35799022 DOI: 10.1007/s43032-022-01022-w.

References

Burnstock G . Short- and long-term (trophic) purinergic signalling. Philos Trans R Soc Lond B Biol Sci. 2016; 371(1700). PMC: 4938022. DOI: 10.1098/rstb.2015.0422. View

Tavares A, Batis J, Papin C, Jennings D, Alagille D, Russell D . Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans. J Nucl Med. 2013; 54(10):1760-7. DOI: 10.2967/jnumed.113.119933. View

McInnes I, Cruwys S, Bowers K, Braddock M . Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism. Clin Exp Rheumatol. 2014; 32(6):878-82. View

Franchi F, Rollini F, Rivas J, Rivas A, Agarwal M, Briceno M . Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing. JACC Basic Transl Sci. 2020; 5(5):419-428. PMC: 7251226. DOI: 10.1016/j.jacbts.2020.02.009. View

Calogiuri G, Al-Sowaidi S, Nettis E, Cortellini G, Macchia L, Vacca A . A joint allergist/cardiologist classification for thienopyridines hypersensitivity reactions based on their symptomatic patterns and its impact on the management strategies. Int J Cardiol. 2016; 222:509-514. DOI: 10.1016/j.ijcard.2016.07.115. View

Piccolo R, Avvedimento M, Canonico M, Gargiulo P, Paolillo R, Conti V . Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovasc Drugs Ther. 2022; 37(5):1031-1038. DOI: 10.1007/s10557-021-07302-y. View

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass T . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14):1505-16. DOI: 10.1016/j.jacc.2006.11.044. View

Ohashi Y, Munesue M, Shimazaki J, Takamura E, Yokoi N, Watanabe H . Long-Term Safety and Effectiveness of Diquafosol for the Treatment of Dry Eye in a Real-World Setting: A Prospective Observational Study. Adv Ther. 2019; 37(2):707-717. PMC: 7004437. DOI: 10.1007/s12325-019-01188-x. View

Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K . Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001; 42(1):96-100. View

10.

Dittrich H, Gupta D, Hack T, Dowling T, Callahan J, Thomson S . The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007; 13(8):609-17. DOI: 10.1016/j.cardfail.2007.08.006. View

11.

Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G . Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. Circulation. 2020; 142(5):441-454. PMC: 7392586. DOI: 10.1161/CIRCULATIONAHA.120.046928. View

12.

Harrington R, Stone G, McNulty S, White H, Lincoff A, Gibson C . Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361(24):2318-29. DOI: 10.1056/NEJMoa0908628. View

13.

Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux J . Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2020; 75(20):2588-2597. DOI: 10.1016/j.jacc.2020.03.059. View

14.

Dota A, Sakamoto A, Nagano T, Murakami T, Matsugi T . Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats. Clin Ophthalmol. 2020; 14:1019-1024. PMC: 7132003. DOI: 10.2147/OPTH.S242764. View

15.

Schilling U, Dingemanse J, Ufer M . Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Clin Pharmacokinet. 2020; 59(5):545-566. DOI: 10.1007/s40262-020-00864-4. View

16.

Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica J, Sroka W . Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2015; 37(3):245-52. PMC: 4712351. DOI: 10.1093/eurheartj/ehv547. View

17.

Jeong Y, Oh J, Yoon H, Park Y, Suh J, Lee S . Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. Thromb Haemost. 2021; 121(10):1376-1386. DOI: 10.1055/a-1346-3300. View

18.

Urooj Zafar M, Baber U, Smith D, Sartori S, Contreras J, Rey-Mendoza J . Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost. 2017; 117(10):1981-1988. DOI: 10.1160/TH17-04-0277. View

19.

Keystone E, Wang M, Layton M, Hollis S, McInnes I . Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012; 71(10):1630-5. DOI: 10.1136/annrheumdis-2011-143578. View

20.

Lordkipanidze M, Marquis-Gravel G, Tanguay J, Mehta S, So D . Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. CJC Open. 2021; 3(6):814-821. PMC: 8209390. DOI: 10.1016/j.cjco.2020.11.021. View